Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge.
作者信息
Vincent Benjamin G, Szustakowski Joseph D, Doshi Parul, Mason Michael, Guinney Justin, Carbone David P
机构信息
Department of Medicine, Division of Hematology/Oncology, Department of Microbiology and Immunology, Curriculum in Bioinformatics and Computational Biology, Computational Medicine Program, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Bristol Myers Squibb, Princeton, NJ.
出版信息
JCO Precis Oncol. 2021 Nov;5:51-54. doi: 10.1200/PO.20.00371.
Abstract
摘要
相似文献
1
Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge.通过众包数据挑战寻找更好的癌症免疫治疗反应生物标志物
JCO Precis Oncol. 2021 Nov;5:51-54. doi: 10.1200/PO.20.00371.
2
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.肿瘤突变负荷（TMB）：一种很有前景的免疫反应生物标志物，也是推进靶向治疗试验的潜在先锋。
Cancer Gene Ther. 2020 Dec;27(12):841-853. doi: 10.1038/s41417-020-0174-y. Epub 2020 Apr 28.
3
Current status of immunotherapy for advanced gastric cancer.晚期胃癌免疫治疗的现状。
Jpn J Clin Oncol. 2021 Jan 1;51(1):20-27. doi: 10.1093/jjco/hyaa202.
4
Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.肺癌辅助和新辅助免疫治疗的最新进展和未来展望。
Jpn J Clin Oncol. 2021 Jan 1;51(1):28-36. doi: 10.1093/jjco/hyaa187.
5
Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.肉瘤：免疫生物标志物表达和检查点抑制剂试验。
Cancer Treat Rev. 2020 Dec;91:102115. doi: 10.1016/j.ctrv.2020.102115. Epub 2020 Oct 20.
6
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.Gr-MDSC相关指标作为接受纳武单抗二线治疗的经治非小细胞肺癌潜在免疫生物标志物。
Clin Transl Oncol. 2020 Apr;22(4):603-611. doi: 10.1007/s12094-019-02166-z. Epub 2019 Jun 28.
7
Immunotherapy and predictive immunologic profile: the tip of the iceberg.免疫治疗和预测性免疫特征：冰山一角。
Med Oncol. 2021 Mar 31;38(5):51. doi: 10.1007/s12032-021-01497-8.
8
CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.CheckMate 743：恶性胸膜间皮瘤的一线希望
Clin Lung Cancer. 2021 Mar;22(2):71-73. doi: 10.1016/j.cllc.2020.11.009. Epub 2020 Dec 2.
9
[Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].伊匹木单抗-纳武单抗作为转移性非小细胞肺癌的一线治疗方案
Bull Cancer. 2021 Mar;108(3):231-233. doi: 10.1016/j.bulcan.2021.01.005. Epub 2021 Feb 20.
10
Immunotherapy as a Downstaging Therapy for Liver Transplantation.免疫疗法作为肝移植的降期治疗方法。
Hepatology. 2020 Oct;72(4):1488-1490. doi: 10.1002/hep.31234.
引用本文的文献
1
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.癌症免疫反应性的理解与治疗性调控进展：癌症免疫治疗学会（SITC）综述
J Immunother Cancer. 2025 Jan 16;13(1):e008876. doi: 10.1136/jitc-2024-008876.
2
A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.非小细胞肺癌免疫检查点阻断后临床结局预测的社区挑战。
J Transl Med. 2024 Feb 21;22(1):190. doi: 10.1186/s12967-023-04705-3.
3
Multi-institutional prognostic modeling of survival outcomes in NSCLC patients treated with first-line immunotherapy using radiomics.采用放射组学对一线免疫治疗的 NSCLC 患者生存结局进行多机构预后建模。
J Transl Med. 2024 Jan 10;22(1):42. doi: 10.1186/s12967-024-04854-z.
4
The Future of Precision Oncology.精准肿瘤学的未来。
Int J Mol Sci. 2023 Aug 9;24(16):12613. doi: 10.3390/ijms241612613.
5
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study.放射组学方法预测免疫治疗晚期非小细胞肺癌患者 PD-L1 和无进展生存期：一项多机构研究。
Sci Rep. 2023 Jul 8;13(1):11065. doi: 10.1038/s41598-023-38076-y.
6
Exploring Novel Innovation Strategies to Close a Technology Gap in Neurosurgery: HORAO Crowdsourcing Campaign.探索神经外科学技术差距的创新策略：HORAO 众包活动。
J Med Internet Res. 2023 Apr 28;25:e42723. doi: 10.2196/42723.
本文引用的文献
1
Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms.联合人工智能和放射科医生评估解读筛查性乳房 X 光照片的效果。
JAMA Netw Open. 2020 Mar 2;3(3):e200265. doi: 10.1001/jamanetworkopen.2020.0265.
2
Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.多发性骨髓瘤 DREAM 挑战赛揭示了表观遗传调节因子 PHF19 作为侵袭性疾病的标志物。
Leukemia. 2020 Jul;34(7):1866-1874. doi: 10.1038/s41375-020-0742-z. Epub 2020 Feb 14.
3
Current Challenges in Cancer Immunotherapy: Multimodal Approaches to Improve Efficacy and Patient Response Rates.癌症免疫疗法当前面临的挑战：提高疗效和患者反应率的多模式方法
J Oncol. 2019 Feb 28;2019:4508794. doi: 10.1155/2019/4508794. eCollection 2019.
4
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.T 细胞功能障碍和耗竭的特征可预测癌症免疫疗法的反应。
Nat Med. 2018 Oct;24(10):1550-1558. doi: 10.1038/s41591-018-0136-1. Epub 2018 Aug 20.
5
Alternative models for sharing confidential biomedical data.共享机密生物医学数据的替代模式。
Nat Biotechnol. 2018 May 9;36(5):391-392. doi: 10.1038/nbt.4128.
6
The Immune Landscape of Cancer.癌症的免疫全景。
Immunity. 2018 Apr 17;48(4):812-830.e14. doi: 10.1016/j.immuni.2018.03.023. Epub 2018 Apr 5.
7
The application of crowdsourcing approaches to cancer research: a systematic review.众包方法在癌症研究中的应用：一项系统综述。
Cancer Med. 2017 Nov;6(11):2595-2605. doi: 10.1002/cam4.1165. Epub 2017 Sep 29.
8
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
9
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.转移性去势抵抗性前列腺癌患者总生存期的预测：通过利用公开临床试验数据的众包挑战开发预后模型。
Lancet Oncol. 2017 Jan;18(1):132-142. doi: 10.1016/S1470-2045(16)30560-5. Epub 2016 Nov 16.
10
Crowdsourcing biomedical research: leveraging communities as innovation engines.众包生物医学研究：将社区作为创新引擎加以利用。
Nat Rev Genet. 2016 Jul 15;17(8):470-86. doi: 10.1038/nrg.2016.69.
Zotero 插件